The Pituitary World News Podcast

S6E13: 7. Laws, guidelines and best practices in new drug development

Our 7th podcast in the series  "The Journey to a New Drug," dives into the regulatory environment with Crinetics Pharmaceuticals regulatory affairs team, Senior Director Michael Monahan, and Operations Manager Debbie Koh Mendez. Crinetics is developing several new oral drugs for Acromegaly and Cushing's.  This podcast is an engaging talk rich with information from two extremely experienced executives. They give us a thorough insiders look at their work with regulatory agencies in the US and Europe. And, given the current issues with COVID-19 vaccine and therapy development, this podcast offers a very educational, timely discussion.  So if you want to learn more about the regulations for the approval of new drugs this is your chance.

Toward the end of the podcasts, don't miss a great discussion on the latest trend in patient involvement and seeking patient insight in the regulatory environment.

S6E12: The challenge of early diagnosis in acromegaly. We can do this!

In this podcast, Dr.  Blevins dives into those clinical features of Acromegaly with a fascinating discussion about symptoms and signs and gives us an unfettered glimpse into the complexities that invariably lead to delays in diagnosis.  Please listen to the podcast at the end of which there is a brief survey.

S6E11: The complex diagnosis of Cushing's syndrome

In this engaging podcast about the diagnosis of Cushing's syndrome, Pituitary Worlds News co-founder and Medical Director, California Center for Pituitary Disorders at UCSF
Professor of Clinical Medicine and Clinical Neurological Surgery, Dr. Lewis Blevins shares a case to illustrate the complexities of diagnosing Cushing's syndrome.  He focuses on the evaluation of patients with hypercortisolism and applying the salivary cortisol profile.

S6E10: Critical COVID-19 information for pituitary patients

We caught up with Dr. Kevin Yuen, medical director of the Barrow Pituitary Center and the Barrow Neuroendocrinology Clinic in Phoenix, Arizona, and  Dr. Lewis Blevins Medical Director of the California Center for Pituitary Disorders at UCSF  and PWN cofounder to discuss important information for pituitary patients regarding COVID-19.

Listen to the podcast and learn:

• about the types of pituitary patients that are more susceptible to COVID-19 infection;
• why and how acromegaly and Cushing's patients are prone to develop diabetes and what they should do if faced with a COVID-19 infection;
• the increased risk of infection of patients with adrenal insufficiency and Cushing's and how to stress dose if they develop symptoms.
• why do active Cushing's syndrome patients need to be aware of the additional treatment steps that are essential to reduce susceptibility to COVID-19.
• what should you do if you suspect infection by COVID-19?  And what steps are needed in case of being quarantined at home?
• what specific signs or symptoms you need to look out for to monitor for progress or deterioration while being quarantined?  And what should you do if you feel you need to seek help?

Don't miss this extremely informative podcast and please send us your comments through our social media channels, on our website or email to info@pituitaryworldnews.com

S6E9: About the risk of infections in pituitary patients: One Doctor's opinion

In this timely podcast Dr. Lewis Blevins, PWN co-founder, and Medical Director, California Center for Pituitary Disorders at UCSF Professor of Clinical Medicine and Clinical Neurological Surgery, provides an in-depth discussion of viral infections specifically for people with pituitary disease.

S6E8: 6. The clinical trial process in new drug development

Dr. Alan Krasner, Chief Medical Officer, and Dr. Chris Cook, Medical Director, Endocrinology at Crinetics Pharmaceuticals offer an in-depth look at clinical studies.  In this podcast, we cover a promising molecule - CRNOO808 - under development for acromegaly and neuroendocrine tumors (NET's), and another hopeful new drug for pediatric congenital hyperinsulinism.  They talked about the challenges, their hopes for new therapeutic strategies, the complexities of their work, and how patients can get involved with industry and government regulators to improve these drugs and therapies.   Click here to listen to more podcasts.

S6E7: Coronavirus

From Jorge Faccinetti and Lewis Blevins, M.D. - In today's podcasts, I ask Dr. Lewis Blevins, PWN co-founder and Medical Director, California Center for Pituitary Disorders at UCSF, Professor of Clinical Medicine and Clinical Neurological Surgery, about his views on the Coronavirus (COVID-19). We discuss the current situation from a physician's perspective of what could be a very worrisome global situation.

S6E6: 5. The fascinating work of discovering a new molecule

Today we continue our series on new drug development – “the journey to a new drug.” This is a captivating conversation with Dr. Stacy Markison - who is Crinetics senior director of Pharmacology and Toxicology - about the science of discovery and the work that goes into making sure a compound is safe for human studies and does what it’s supposed to do.

S6E5: Tackling unmet needs: new compounds in development for non-functioning pituitary adenomas and rare endocrine diseases

In today's podcast, we highlight a new company dedicated to the rare endocrine disease world.  Tiburio Therapeutics is working on two exciting compounds for the treatment of Non-functioning Pituitary Adenomas and rare endocrine disorders.

Last week Dr. Blevins and I caught up with Abe Ceesay, Tiburio CEO and Nerissa Kreher M.D., Chief Medical Officer, both highly experienced professionals in the rare endocrine space. We had a fascinating talk about their plans in this area of extensive need for patients. Here’s our talk.

S6E4: 4. "The journey to a new drug": understanding molecules and receptors

This podcast, the fourth in our drug development series “the journey to a new drug,” brings you my conversation with Dr. Stephen Betz, cofounder at Crinetics Pharmaceutical. Our discussion spotlights new drugs for acromegaly, Cushing’s, and pediatric hyperinsulinism, currently under development at Crinetics. It includes a fascinating talk on molecules and how they work with cell receptors to eventually provide a launching pad for new drugs.

We hope this podcast will serve up a better understanding of the many steps required to find and bring new medications and therapies to patients.